Nisa Investment Advisors
NTLA icon

Nisa Investment Advisors’s Intellia Therapeutics NTLA Stock Holding History

Nisa Investment Advisors’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$131K Buy
7,725
+1,627
+27% +$22.8K ﹤0.01% 1424
2026
Q1 		$78.2K Sell
6,098
-25,637
-81% -$327K ﹤0.01% 1517
2025
Q4 		$285K Buy
31,735
+30,351
+2,193% +$418K ﹤0.01% 1142
2025
Q3 		$23.9K Buy
1,384
+124
+10% +$1.53K ﹤0.01% 1916
2025
Q2 		$11.8K Sell
1,260
-958
-43% -$7.87K ﹤0.01% 2190
2025
Q1 		$15.8K Buy
2,218
+1,382
+165% +$14K ﹤0.01% 1976
2024
Q4 		$9.75K Sell
836
-288
-26% -$4.5K ﹤0.01% 2143
2024
Q3 		$23.1K Buy
1,124
+56
+5% +$1.29K ﹤0.01% 1870
2024
Q2 		$23.9K Sell
1,068
-1,228
-53% -$29.2K ﹤0.01% 1884
2024
Q1 		$63.2K Sell
2,296
-64
-3% -$1.78K ﹤0.01% 1601
2023
Q4 		$72K Sell
2,360
-100
-4% -$2.87K ﹤0.01% 1536
2023
Q3 		$77.8K Sell
2,460
-59,990
-96% -$2.33M ﹤0.01% 1588
2023
Q2 		$2.55M Buy
62,450
+60,470
+3,054% +$2.45M 0.02% 609
2023
Q1 		$74K Buy
1,980
+20
+1% +$784 ﹤0.01% 1598
2022
Q4 		$68K Sell
1,960
-112
-5% -$5.33K ﹤0.01% 1681
2022
Q3 		$109K Buy
2,072
+552
+36% +$34.2K ﹤0.01% 1465
2022
Q2 		$79K Sell
1,520
-350
-19% -$17.8K ﹤0.01% 1572
2022
Q1 		$136K Sell
1,870
-1,220
-39% -$103K ﹤0.01% 1517
2021
Q4 		$292K Sell
3,090
-23,401
-88% -$2.93M ﹤0.01% 1156
2021
Q3 		$3.55M Buy
26,491
+23,441
+769% +$3.55M 0.02% 549
2021
Q2 		$494K Hold
3,050
– – ﹤0.01% 1142
2021
Q1 		$245K Hold
3,050
– – ﹤0.01% 1416
2020
Q4 		$166K Buy
3,050
+950
+45% +$34.5K ﹤0.01% 1551
2020
Q3 		$42K Buy
+2,100
New +$43.8K ﹤0.01% 1860
2018
Q4 		– Sell
-17,100
Closed -$489K – 1976
2018
Q3 		$489K Buy
17,100
+9,100
+114% +$265K ﹤0.01% 1101
2018
Q2 		$219K Hold
8,000
– – ﹤0.01% 1243
2018
Q1 		$169K Hold
8,000
– – ﹤0.01% 1272
2017
Q4 		$154K Hold
8,000
– – ﹤0.01% 1313
2017
Q3 		$199K Buy
8,000
+100
+1% +$1.88K ﹤0.01% 1251
2017
Q2 		$134K Buy
+7,900
New +$110K ﹤0.01% 1309

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

Nisa Investment Advisors's NTLA Position: Q2 2026 in Review

Nisa Investment Advisors increased its Intellia Therapeutics (NTLA) stake by 27% in Q2 2026, buying an estimated $22.8K and bringing the position to 7,725 shares worth $131K. The position accounts for ﹤0.01% of the portfolio, ranked #1424.

Nisa Investment Advisors first reported a position in NTLA in Q2 2017 and has held it in 30 quarters since. The position peaked at $3.55M in Q3 2021. 328 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

  • Nisa Investment Advisors held 7,725 shares of Intellia Therapeutics worth $131K as of Q2 2026.
  • Nisa Investment Advisors bought 1,627 Intellia Therapeutics shares in Q2 2026, an estimated $22.8K.
  • Intellia Therapeutics made up ﹤0.01% of Nisa Investment Advisors's portfolio in Q2 2026, its #1424 holding.
  • Nisa Investment Advisors first reported a position in Intellia Therapeutics in Q2 2017 and has held it in 30 quarters since.
  • Nisa Investment Advisors's Intellia Therapeutics position peaked at $3.55M in Q3 2021.
  • 328 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on Nisa Investment Advisors's 13F filing for Q2 2026, filed 10 Aug 2026.